Edgewise Therapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Edgewise Therapeutics Inc
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
/ 
Frequently asked questions
To buy Edgewise Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Edgewise Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Edgewise Therapeutics Inc is EWTX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Edgewise Therapeutics Inc has its primary listing on NASDAQ. You can trade Edgewise Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Edgewise Therapeutics Inc is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Edgewise Therapeutics Inc as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Edgewise Therapeutics Inc or others.